Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edap Technomed.

This article was originally published in The Gray Sheet

Executive Summary

Investigational device exemption is slated for submission by the end of the second quarter for the Ablatherm high-intensity focused ultrasound system for the treatment of prostate cancer. Edap's proposed clinical trial protocol would study patients not responsive to radiation therapy. Ablatherm uses high-temperature ultrasound delivered via a rectal probe to ablate cancerous prostate cells. The firm also has a premarket approval application supplement pending with the agency for a "compact version" of its Prostatron transurethral microwave thermotherapy treatment for benign prostate hyperplasia. The device will be sold to smaller hospitals and to the urology office market at a reduced price compared to current versions of the system. Bard's Urological Division, which co-markets the current Prostatron line, also will co-market the compact system...

You may also be interested in...



ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors

Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel